Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic Impairment

Ertugliflozin, an oral, highly selective inhibitor of the sodium-glucose cotransporter 2, is approved in the United States and the European Union for the treatment of adults with type 2 diabetes mellitus. Hepatic impairment may affect, to varying degrees, the absorption, metabolism, and excretion of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical therapeutics 2018-10, Vol.40 (10), p.1701-1710
Hauptverfasser:	Sahasrabudhe, Vaishali, Terra, Steven G., Hickman, Anne, Saur, Didier, Raje, Sangeeta, Shi, Haihong, Matschke, Kyle, Zhou, Susan, Cutler, David L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adults Blood pressure Body mass Body mass index Body size Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Dosage Drug dosages Drug metabolism ertugliflozin Excretion FDA approval Feces hepatic impairment Impairment Liver Metabolism Metabolites Patients Pharmacokinetics Pharmacology Proteins Radioactive half-life Radioactivity SGLT2 inhibitor Sodium Sodium-glucose cotransporter Urine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!